Skip to content

Moderna

US · MRNA #406 by market cap Listed 2018
195.00 -4.33 -2.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 13.22 Expensive vs history 99th percentile
5-year average 3.30 · #471 of 514 in Biotechnology
P/E ratio -31.73 Cheap vs history 1st percentile
5-year average -0.19 · forward -37.64
P/S ratio 35.79 Expensive vs history 98th percentile
5-year average 6.37 · forward 39.51 · #249 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%
Revolution Medicines (RVMD) 34.87B -17.66 14.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value212.00 Economic moatNone UncertaintyVery High Capital allocationStandard

Trading 8.7% below Morningstar's fair value estimate.

Analyst note

Moderna held an analyst day on Nov. 12 at its Marlborough manufacturing facility, the site of production of its personalized oncology treatment, intismeran. Shares fell 7%.

Why it matters: As Moderna and partner Merck prepare to file for Food and Drug Administration approval of intismeran in early-stage melanoma by the end of the year, investors are eager to learn more about the firm's preparations for a potential launch in 2027, including manufacturing progress. We were impressed by Moderna's already significant progress in reducing intismeran manufacturing costs (down 50% from the initial process) as well as its flexibility to quickly add capacity at the Marlborough site as needed. Given next-generation processes in the works that could support even more efficient and automated manufacturing within the next couple of years, capacity estimates have a wide range, but management noted that Marlborough can support tens of thousands of patients annually.

The bottom line: We're maintaining our $212 fair value estimate for no-moat Moderna following the meeting, but with a close eye on upcoming data. We think shares look relatively fairly valued after Nov. 12's close. We still build in $12 billion in annual oncology revenue by 2035, driven by intismeran. Moderna's projected $4.0 billion-$4.5 billion in annual cash costs for 2027-30 is in line overall with our current model, albeit slightly more front-loaded due to the aggressive continued intismeran investment. We think the excellent phase 3 melanoma data support this decision. The framework for an economic moat is clearly being erected, and we're watching upcoming data to help sort out the breadth of the opportunity beyond vaccines.

Coming up: We still expect a pivotal readout for Moderna's lead rare disease program in propionic acidemia this year, which would be a gating event for additional investment. However, phase 2 data for intismeran in kidney cancer may not be available until 2027, based on event rates.

BLANK PAGEOne of the central questions for Moderna investors right now is whether intismeran will work for cancers beyond melanoma. Moderna's chief development officer, Dr. David Berman, made a compelling case for why it could, highlighting intismeran's ability to activate new T-cells (as opposed to Keytruda's ability to revive exhausted T-cells), phase 2 melanoma data showing efficacy in patients with lower tumor mutation burden (that is, a lower number of mutations in their cancer cells, which could indicate potential efficacy in other cancers with generally lower numbers of mutations), as well as the sheer magnitude of benefit in melanoma studies. We agree that the 42% reduction in risk of progression or death in the phase 3 melanoma study allows room for a significant efficacy benefit in other cancers, even if the benefit is slightly less impressive. While we still probability-weight our forecast for intismeran beyond melanoma, we think there is a greater likelihood of success than failure, and we use a 60% probability of approval for key indications in testing (lung, kidney, and bladder cancers). Overall, combined with our assumption that intismeran will be approved in melanoma in 2027, this results in $9.6 billion worth of intismeran sales flowing to Moderna annually by 2035, or a total of $19.2 billion in global revenue split between Moderna and partner Merck.

Fair value

We’ve raised our Moderna fair value estimate to $212 per share from $163 after increasing our covid revenue expectations by roughly $200 million annually over our 10-year explicit forecast period and boosting our potential market size estimates for the oncology pipeline. Overall, we now include $12 billion in cancer-related revenue in our Moderna model annually by 2035, with nearly $10 billion of this from Intisermon (as part of a 50/50 split with partner Merck), $1.6 billion from mRNA-2808, and $900 million from phase 2 cancer antigen therapy mRNA-4359.

We think Moderna’s covid vaccine revenue could flatten around $2 billion globally in the long run. Despite continued regulatory headwinds on vaccines in the US, we think Moderna will continue to gain traction internationally with strategic agreements outside the US and potential new EU covid vaccine contracts beginning in 2027.

The company is facing several headwinds that are making its previously aggressive R&D strategy less feasible, including weak demand for covid vaccines, entrenched competition in RSV, no Accelerated Approval pathway for its melanoma treatment, and a shrinking pool of cash from pandemic covid vaccine profits. Moderna is therefore focusing its cash and R&D efforts on 10 programs it expects to reach the market by 2028. With 2026 costs elevated from a $950 million litigation charge in the first quarter, we expect Moderna to further chip away at losses in 2027 and turn a profit in 2029, assuming a successful launch of intismeran in melanoma (and broader flu vaccine launch) in 2027.

We expect that Moderna’s launches of prophylactic infectious-disease vaccines for RSV (2024) and influenza (2026-27 in international markets) will help support sales growth, although competition could slow the sales trajectory. We assume $4.3 billion in annual infectious-disease vaccine sales outside of covid by 2035. We assume a 100% probability of approval for Merck and Moderna’s personalized cancer vaccine, intismeran, in melanoma and a 60% probability of approval in lung cancer, and we expect Moderna could record $9.6 billion in sales from the program by 2035. We include $1 billion in annual sales from rare-disease therapeutics by 2034 (20%-50% probabilities of approval). Overall, this results in more than $19 billion in total probability-adjusted annual revenue by 2035. We expect operating margins to surpass 30% by 2030, even with continued strong investment in research and development.

Under our updated discount rate framework, we estimate Moderna’s weighted average cost of capital at 9.2%, using a beta of 1.04 based on stock fundamentals and market returns.

Economic moat

The stellar safety and efficacy profile of Moderna's covid vaccine rapidly validated the firm's mRNA technology, and we expect returns on invested capital to exceed our 9.2% assumed cost of capital beginning in 2032. However, we see significant threats of value destruction that keep the firm from having a narrow moat. Moderna served a critical role in vaccinating millions of individuals during the pandemic and has several potential first-in-class vaccines and therapies in testing that could serve significant unmet needs. However, its ability to launch differentiated mRNA therapies beyond covid, ranging from prophylactic vaccines for other respiratory diseases to cancer treatments, will be key to establishing a moat, in our opinion. Also, lower covid vaccination rates have shrunk Moderna’s funding and forced it to narrow its pipeline focus. In addition, we see uncertainty regarding its defenses against other firms using mRNA technology and related to the US policy environment surrounding vaccines and mRNA.

Moderna's platform technology allows new genetic sequences to be easily inserted to create new therapies, and virtually identical, cell-free, low-volume manufacturing across programs should allow flexible manufacturing, but these characteristics—which allowed it to vault to the lead ahead of older technologies during the pandemic—could also make it more vulnerable to other competitors with similar technologies. Moderna's medicines use mRNA, which the company refers to as “the software of life,” to deliver instructions for a patient's own body to produce a given protein, which can either trigger an immune reaction (prophylactic vaccines like the covid vaccine, or oncology vaccine programs) or replace a protein that is missing or faulty. Moderna's IP protection stems from the firm's broad mRNA technology (including sublicensed patents), formulation (including methods of using specific, proprietary lipid nanoparticle delivery technologies), and also the exact composition of matter (encoded antigen) for individual products. Protection extends through at least 2033 for issued patents and to 2036 (EU) and 2041 (US) for approved covid and RSV vaccines. Despite these patents, competition could come from established vaccine firms partnering with innovative mRNA firms (GSK/CureVac and Sanofi's Translate acquisition), other mRNA firms (BioNTech), or vaccines using other technologies (including Pfizer's and GSK's protein-based RSV vaccines). That said, Moderna's experience with artificial intelligence and proprietary digital technologies could allow it to design the best mRNA sequences for protein expression, and pandemic vaccine profits could give it an edge in ongoing proprietary work on new delivery technologies and lipid nanoparticles.

Despite the early lead that Moderna and BioNTech hold after developing their covid vaccines in less than a year and their clear dominance in covid vaccine sales, the long-term covid vaccine market is mired in uncertainty. The virulence of new strains and the population's willingness to continue to get vaccinated remain key questions. We assume that many high-risk individuals in developed markets continue to get annual vaccines, although we do not assume regular vaccination for healthy adults, leading us to a roughly $2 billion annual long-term covid vaccine opportunity for Moderna, well below peak sales near $18 billion annually in 2021 and 2022.

Among Moderna's infectious-disease vaccines beyond covid, the first to gain approval was mResvia for RSV. While it launched in time for the 2024-25 season, tough competition from Pfizer and GSK vaccines launched in 2023 as well as the multiyear protection of the vaccine have limited Moderna’s market opportunity here.

In the vaccine pipeline, influenza and norovirus (stomach flu) programs are leading, with launches aimed at 2027-28. While the $6 billion global influenza vaccine market is already crowded and has poor pricing power, Moderna's technology appears to allow higher efficacy than traditional vaccines, which in a good year are only 60% effective. With a shorter lead time due to faster manufacturing, Moderna should see a higher likelihood of targeting the key strains that will circulate in the upcoming season. Moderna's combination covid and influenza vaccine received approval in Europe in April 2026, and the stand-alone influenza vaccine received US FDA approval in August 2026, despite a rockier path to approval due to controversy over its trial design and vaccine skepticism under the supervision of Robert F. Kennedy Jr., the secretary of Health and Human Services. We’re still waiting for clarity on the approval pathway for the covid/flu combination vaccine in the US, which we think is key to uptake; the convenience of a combination shot could draw some of the 150 million Americans who receive a flu shot each year to receive Moderna's combination shot instead. Moderna's potential first-to-market norovirus vaccine failed at its interim analysis in 2026, but Moderna is discussing data with regulators.

In oncology, Moderna aims to activate a cancer patient's T cells by administering mRNA encoding neoantigens (antigens unique to tumor cells). One approach, in partnership with Merck, is an individualized neoantigen therapy that treats cancer by administering mRNA encoding multiple tumor neoantigens that T-cells can recognize, allowing a patient's immune system to recognize tumors more easily. Moderna and Merck have reported positive data for intismeran in a phase 3 melanoma trial, and we assume a 60% probability of success in an even larger adjuvant lung cancer indication (with three phase 3 trials in progress). Moderna's pipeline is also beginning to fill with off-the-shelf cancer therapies, including additional cancer antigen therapies, T-cell engagers, and in vivo CAR-T therapies, all based on Moderna's mRNA technology.

Bull case

The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology.

Its mRNA technology could allow the firm to compete in a wide range of therapeutic areas, from other prophylactic vaccines (like influenza and other viruses) to enzyme replacement (various rare diseases) to cancer.

Moderna's cash infusion from covid vaccine sales in 2021-22, as well as newly established large-scale manufacturing facilities, positions the firm to rapidly develop new pipeline programs.

Bear case

Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.

Continued evolution of less threatening variants, society's vaccine fatigue, and uncertain US policy changes have significantly reduced demand for Moderna's covid vaccine.

Established, non-mRNA competition in RSV and influenza could make it difficult for Moderna to gain market share with new vaccines.

By Karen Andersen, CFA

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Moderna discussion 0 comments

Add a comment